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Objective: Diabetes is a leading risk factor for the development of peripheral arterial disease (PAD). The
optimal imaging modality for patients with diabetes and PAD is uncertain. We sought to analyse the
literature to determine the accuracy of contrast enhanced magnetic resonance angiography (CE-MRA) in
differentiating extent of disease in patients with infragenicular PAD and diabetes, using digital sub-
traction angiography (DSA) as the gold standard.
Methods: Online databases were searched for relevant keywords (January 1998eJune 2012). Eligible
studies prospectively compared CE-MRA and DSA of infragenicular vessels and provided data to
construct contingency tables in at least 10 patients with diabetes and PAD symptoms. Pooled sensitivity
and speciﬁcity values were calculated using random effects modelling.
Results: Only three studies (83 patients) provided data regarding the infragenicular vessels. The pooled
sensitivity of MRA was 86% while the pooled speciﬁcity of MRA was 93%.
Conclusions: The assumptions regarding CE-MRA’s efﬁcacy for infragenicular disease in diabetics are
based upon low patient numbers. Inadequate diagnostic imaging in this high-risk group risks adoption of
incorrect revascularisation strategies. Further studies are required.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
The prevalence of diabetes is projected to increase in the coming
decades.1 Diabetic patients have a 2.5e4.0-fold increased risk of
developing peripheral arterial disease (PAD)2,3 with a well-
established tendency to below knee disease.4,5 Symptomatic PAD in
diabetic patients may be treated using open or endoluminal revas-
cularisation techniques. Infra-inguinal bypass carries an increased
risk of adverse events in diabetic patients6 while 5-year primary
patency rates are lower in diabetics compared to non-diabetics
following endoluminal infra-inguinal revascularisation.7 Multi-level
disease is more common among diabetics7 potentially complicating
treatment decisions. Thus, accurate imaging is essential for decision-
making in diabetic patients requiring intervention for PAD.
Digital subtraction angiography is the traditional gold-standard
for imaging PAD and allows the opportunity to proceed directly
with endovascular revascularisation. However, DSA is invasive and
carries a risk of contrast nephropathy, particularly in diabetic pa-
tients.8 Magnetic resonance angiography (MRA) does not require
arterial puncture and is viewed as a less-invasive, more acceptablelarke Moloney).
ciates Ltd. Published by Elsevier Ltform of imaging. Data from studies conducted in general PAD pa-
tients suggest that it has excellent sensitivity and speciﬁcity for
infra-inguinal steno-occlusions.9 MRA also incurs lower costs
within the radiology department.10 Its accuracy in diabetic patients,
particularly for infragenicular disease, is unclear. Interpretative
errors due to acquisition artefacts are not uncommon.11 These may,
in turn, lead to erroneous decisions to intervene percutaneously,
exposing the patient to the risk of contrast nephropathy, or inter-
vene surgically, exposing the patient to all the attendant risks. A
further associated risk when gadolinium based contrast agents are
used is that of nephrogenic systemic ﬁbrosis (NSF). NSF, is rare (less
than 500 cases in published medical literature12) and decreasing in
incidence, but has serious consequences. Carbon dioxide angiog-
raphy is a relatively safe alternative, though it is limited by inac-
curacy below the knee.13 Duplex ultrasound is accurate (88%
sensitivity14) but, again, is limited below the knee15 while contrast
enhanced computed tomography angiography (CTA) is accurate
(91% sensitivity14) but limited by exposure to iodinated contrast
agents and radiation. As the optimal imaging modality in diabetics
is not established, we undertook a systematic review and meta-
analysis of diagnostic studies in order to determine the overall
sensitivity and speciﬁcity of contrast-enhanced MRA (CE-MRA)
compared to DSA for infragenicular arterial disease in diabetics.d. All rights reserved.
Table 1
Summary of the quality of 2 studies assessed by using the QUADAS tool.
Lapeyre
et al.
Andreisek
et al.
Wang
et al.
1. Representative patient group Yes Yes Yes
2. Clear selection criteria Yes Yes Unclear
3. Acceptable reference standard Yes Yes Yes
4. Acceptable delay between tests Yes Yes Yes
5. Whole sample veriﬁcation and
not selective DSA use
Yes Yes Yes
6. Same reference standard
regardless of index test result
Yes Yes Yes
7. Reference standard independent
of index test
Yes Yes Yes
8. Adequate index test description Yes Yes Yes
9. Adequate reference test
description
Yes Yes Yes
10. MR images interpreted without
DSA result
Yes Yes Yes
11. DSA images interpreted
without MR result
Yes Yes Yes
12. Clinical data available as in
clinical practice
No No No
13. Uninterpretable/intermediate
results reported
Yes Yes No
14. Withdrawals explained Yes Yes Yes
SCORE 13/14 13/14 11/14
Overall quality assessment High High High
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2.1. Study identiﬁcation
The systematic review was performed in accordance with the Preferred
Reporting Items in Systematic Reviews and Meta-analyses guidelines.16 It was
conducted without a written protocol though outcomes were predetermined before
the study commenced. Medline and Embase were searched from 1st January 1998 to
20th June 2012 using the search terms (peripheral arterial disease) AND (magnetic
resonance angiography). English was set as a language restriction. The reference lists
of retrieved articles were scrutinised for further relevant publications. A search of
available online electronic records of published abstracts from conferences of the
Radiological Society of North America, the European Congress of Radiology, the
Society of Vascular Surgery, the Peripheral Vascular Surgery Society and the Vascular
Society of Great Britain and Ireland (1998e2011) was performed to identify studies
published only in abstract form.
2.2. Eligibility criteria
Studies were eligible for inclusion provided that the following criteriawere met:
prospective design, inclusion of adults with suspected PAD and diabetes, use of CE-
MRA with gadolinium based contrast agents (but not blood pool agents), use of
selective intra-arterial DSA as comparison and sufﬁcient data provided to construct
2  2 contingency tables. We excluded studies solely comparing different MRA
techniques without a comparison group, studies that did not examine below knee
arterial segments and studies in which only selected patients underwent DSA. For
studies which reported the inclusion of diabetic patients but provided only gener-
alised results, corresponding authors were contacted in an effort to obtain results for
the diabetic subgroup.
2.3. Data extraction and analysis
Two authors (DH and EB) independently reviewed citation lists and abstracts to
determine article eligibility and inclusion. Inter-observer agreement was evaluated
by means of a kappa statistic. Disagreements were resolved by consultation with a
third reviewer (SRW). For each included study, two authors (DH and EB) extracted
data comprising details on study design, number of participants, imaging and image
analysis protocols, number of segments assessed and raw data on numbers of true
positives, false positives, true negatives and false negatives of CE-MRA when
compared with DSA in the infragenicular arterial tree. Greater than 50% stenosis or
an occlusion was considered a positive segment result. Sensitivity and speciﬁcity
values with raw data were the principle summary measure of included studies.
These data were entered into a computerised spreadsheet for analysis. For meta-
analysis, pooled sensitivity and speciﬁcity values were calculated using random
effects modelling, as was the area under a summary receiver operating characteristic
curve (SROC). Heterogeneity was evaluated using the I2 statistic. Study quality and
bias risk were evaluated at individual study level by using the Quality Assessment of
Diagnostic Accuracy Studies (QUADAS) tool.17 The QUADAS tool is structured around
14 questions which have been validated in the evaluation of diagnostic studies
(Table 1). The statistical analysis was undertaken using Meta-Disc Version 1.4
(Hospital Universitario Ramon y Cajal, Madrid, Spain) and Statsdirect Version 2.5.8
(Statsdirect Ltd., Altrincham, United Kingdom).
3. Results
3.1. Search results
The results of the systematic review are summarised in Fig. 1.
The electronic database literature search identiﬁed 4299 sources.
4193 articles were excluded based on titles and abstracts. 106 full
text articles were screened. Almost half of these full text articles
were excluded due to the absence of diabetic subgroup data. The
search of conference abstracts yielded no relevant studies. When
ineligible studies were excluded, three studies fulﬁlled the criteria
for inclusion in the analysis. The authors agreed fully on article
eligibility, yielding a kappa score of 1.
3.2. Study characteristics
The characteristics of the eligible studies are summarised in
Table 2. The studies were performed on adults with PAD and
compared MRA with DSA for identifying steno-occlusions. Lapeyre
et al.18 and Andreisek et al.19 included only patients with diabetes.
In the study by Wang et al.,20 21/31 patients had diabetes. Diabeticsubgroup data were obtained via email correspondence with the
authors. Lapeyre et al. and Wang et al. included only patients with
critical ischaemia while Andreisek et al. included patients with
both claudication and critical ischaemia. In total, 57/83 patients had
rest pain or ulceration and 26/83 had claudication (Table 2). All
three studies involved two readers separately analysing images.
Andreisek et al. provided separate raw data for both readers.
Lapeyre et al. and Wang et al. provided pooled raw data from both
readers. The studies provided sufﬁcient raw data to allow con-
struction of 2 2 contingency tables, with DSA as the gold standard
and a stenosis of>50% vessel diameter or an occlusion considered a
positive result on DSA and MRA.
Lapeyre et al. used a hybrid MR technique involving two distinct
acquisitions on a 1.5-T scanner. Firstly, the infragenicular area was
examinedwith a 3D gradient-echoT1-weighted fast low-angle shot
spoiled VIBE (volumetric interpolated breath-hold) sequence. Sec-
ondly, three-station bolus chase MR angiography was performed.
Gadoterate dimegluminewas the contrast agent for both sequences.
Andreisek et al., also using a 1.5-Tscanner butwith gadobutrol as the
contrast agent, performed standard three-station bolus chase MR
angiography followed by MR angiography with time resolved im-
aging of contrast kinetics (TRICKS) in the infrapopliteal segments.
Wang et al. used a hybrid technique consisting of two station bolus
chase MRA with TRICKS MR in the infrapopliteal segments. The
three studies used a similar DSA technique.
3.3. Study quality
The methodological quality of the three studies was high
(Table 1). All studies lost a single point as the readers were blinded
to clinical data in both studies. One study20 lost further points as
the selection criteria were not clear and uninterpretable results
were not mentioned.
4. Results
The three studies contained 83 patients. The overall pooled
sensitivity was 0.87 (95% CI 0.86e0.91). There was evidence of
heterogeneity (I2 ¼ 96%). The overall pooled speciﬁcity was 0.93
Eligible for inclusion in metaanalysis
(n = 3)
Excluded after article screening (n=103)
Unable to construct 2x2 tables:27 
Not a diagnostic study:19 
Retrospective design:12 
No diabetic subgroup data (despite effort to 
contact authors):31 
Not involving calf vessels:7 
Selective use of DSA:3 
Not in English:4 
Not relevant after title and abstract review (n = 
4193) 
Full articles screened 
(n =106 )
Potentially relevant articles (electronic databases)
(n =4299 )
Fig. 1. PRISMA ﬂow diagram.
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(I2¼ 66%). The summary ROC curve yielded an area under the curve
of 0.98 (standard error 0.01).5. Discussion
There have been several meta-analyses onMR imaging in PAD in
general.9,14,21e23 The most recent meta-analysis by Menke et al.
found overall pooled sensitivity and speciﬁcity values of 94.7% and
95.6% with below knee respective results of 92.2% and 93.3%.9 A
2007 systematic review quoted median below knee sensitivity and
speciﬁcity of 83% and 92%14 while a 2001 meta-analysis found that
the estimated Q point (equal sensitivity and speciﬁcity) for CE-MRA
was 94% for the entire lower limb.23 A 2000 meta-analysis reported
pooled sensitivity and sensitivity values of 97.5% and 96.2%.22 Until
now, no diabetic subgroup data have been available. Given that
diabetes is associated with a tendency to distal rather than prox-
imal disease, it is worthwhile to speciﬁcally analyse the beneﬁts of
infragenicular MR imaging in this group. The optimal imaging
modality should be clearly identiﬁed in order to hasten revascu-
larisation as poorer outcomes are expected in cases of critical
ischaemia in diabetics. We found that MRA has a sensitivity of 87%
for the detection of infragenicular steno-occlusions in diabetics.
The speciﬁcity of MRA was 93%. These results compare favourably
with those fromMenke et al.9 However, our results suggest that the
sole use of MRA as a tool to guide revascularisation would lead to
considerable misjudgement. It is worth noting that a screening test
is most helpful when it has a high speciﬁcity. Our results suggest
that MRA may be better for screening rather than diagnosis. For
comparative purposes, overall (not speciﬁc to infra-geniculardisease) lower limb sensitivity and speciﬁcity values for DUS in PAD
are 88% and 96% respectively and are 91% and 91% for CTA.14
Our literature search was exhaustive yet yielded just three
studies. This is in comparison with the 32 studies included in the
Menke meta-analysis.9 Two of the included studies were per-
formed solely on diabetics.18,19 In relation to the third included
study,20 diabetic subgroup data were obtained via correspondence.
Despite efforts to contact authors of studies without published
diabetic subgroup results, the response rate was low. Our search
demonstrates the lack of data on the use of MRA in diabetics with
PAD. The absence of this data is of concern given the potential for
complications with both MRA and DSA.
We acknowledge that the included studies involved varying dis-
ease severity and differingMR andDSA techniques. Different disease
severity is a very important consideration as patients with claudi-
cation are likely to have single level disease whereas those with
critical ischaemia oftenhavemulti-level disease24 and, thus, imaging
resultsmay be effected. Heterogeneity could account for some of the
difference in individual study results. We highlight that we did not
seek to clarify which MR technique was most beneﬁcial in diabetics
and that we did not limit our study to speciﬁc disease severity or
imaging techniques. Rather, we sought to include any high quality
CE-MRA/DSA comparative data after 1998. We acknowledge that
techniques were undergoing reﬁnement over the involved time
period. Our aimwas to determine the extent of the evidence base for
the use of CE-MRA in diabetics with PAD. Further strengths of the
article are that there was full agreement among authors concerning
study inclusion and that the included studies were of high meth-
odological quality with QUADAS scores of 11 or greater. The QUADAS
scores achieved by the studies compare favourably with those of the
Menke meta-analysis.
Table 2
Characteristics and results of eligible studies. (MRA-magnetic resonance angiography, DSA-digital subtraction angiogram, PAD-peripheral arterial disease, T-tesla, VIBE-
volumetric interpolated breath-hold examination, TRICKS MR-time resolved imaging of contrast kinetics magnetic resonance, CFA-common femoral artery)).
Lapeyre et al., 2004 Andreisek et al., 2007 Wang et al., 2010
Design Single institution prospective
diagnostic cohort study to
determine diagnostic accuracy
of MRA vs. DSA in diabetics
with PAD
Single institution prospective
diagnostic cohort study to
determine diagnostic accuracy
of MRA vs. DSA in diabetics
with PAD
Single institution prospective cohort
study to determine diagnostic accuracy
of MRA vs. DSA in patients with PAD
Number of
participants
31 31 31
Data on 21 diabetics in the cohort
obtained via correspondence
Extent of disease All had non healing ulcers or
focal gangrene with suspected
vascular cause
26 had intermittent claudication,
1 had rest pain, 4 had non healing
ulcers or focal gangrene
Patients had rest pain, non-healing
foot ulcers or focal gangrene
MRA protocol 1.5T scanner. Infragenicular VIBE
sequence followed by 3 station
bolus chase technique.
Gadoterate dimeglumine was
the contrast agent.
1.5T scanner. 3 station bolus chase
followed by TRICKS MR of the calf
and foot. Gadobutrol was the
contrast agent.
1.5T scanner. 2 station bolus chase followed
by TRICKS MR of the calf and foot. Gadobenate
dimeglumine was the contrast agent.
DSA protocol Experienced angiographers.
Intra-arterial mechanical
iodixanol injection via CFA. No
vasodilator. Anterior views for
fem-pop segments and anterior
and lateral views for the calf
and foot.
Experienced angiographer.
Intra-arterial manual injections of
iodixanol. No vasodilator. Anterior
views except for imaging of foot
and ankle in external rotation.
Experienced angiographers. Intra-arterial
injection of iodixanol in distal external
iliac artery. No vasodilator. Images taken
in two planes.
Delay between
modalities
MRA ﬁrst followed by DSA
within 3 days
DSA followed by MRA (median
delay 1 day, range 1e29)
Median of two days between studies
(range 1e23 days)
Image analysis Two independent readers,
blinded to previous radiology
and clinical data. Analysed
randomly over several days.
Two independent readers, blinded
to previous radiology and clinical
data. Analysed randomly. TRICKS
MR analysed separately 3
weeks later.
DSA analysed by two experienced radiologists
blinded to clinical data and MR images. MR
images analysed separately by two other
readers (MRA experience of ﬁve years and
one year).
Number of segments
assessed
310 segments assessed by
each reader (620 in total)
436 below knee segments
analysed on DSA
620 bolus chase segments
465 DSA segments
341 TRICKS segments
828 segments assessed overall.
Below knee segment
results
Overall results given only Reader 1 Reader 2 Diabetic group results
True positives 247 100 102 187
True negatives 168 141 139 128
False positives 7 15 15 9
False negatives 14 34 25 9
Below knee sensitivity 94.6% 87.7% 80.3% 95.4%
Below knee speciﬁcity 96% 90.4% 90.3% 93.4%
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implications of MR imaging. Two reviewers suggested 83 possible
treatment options (of which 66 were in the infragenicular seg-
ments) based on DSA and all of these were endorsed by the MR
images. This supports the high sensitivity of MRA. However, 11
treatments (of which seven were in the infragenicular segments)
were suggested based on MR images that subsequently were not
mirrored on DSA. The authors suggest distal vessels are more easily
identiﬁed by MRA than DSA. This has been suggested before.25e27
Equally, it could be argued that perhaps MRA exaggerates the size
of distal vessels.
The present study has several limitations. Firstly, just three
clinical studies involving just 83 patients form the basis of our re-
sults. Firm conclusions cannot be drawn from such numbers. For
future diagnostic studies, problems with small numbers can be
improved by a strategy described by Voth et al.28 They described
how increasing the number of readers to three can improve the
power of diagnostic MR studies without compromising validity. A
second limitation is that all relevant data may not have been found,
even though a thorough search was performed and relevant au-
thors were contacted where possible. There was a high non
response rate to requests for diabetic subgroup data, which in-
troduces considerable selection bias. Lastly, the included studies
concern prospective data from 2002 to 2007 and were published in2005, 2007 and 2010. MR scanners and techniques have continued
to increase in sophistication since then. The relevance of conclu-
sions drawn on the basis of dated data may be questioned. How-
ever, the bolus chase MRA technique (as used in the included
studies) has remained reliable, with recent endorsement in a large
2010 meta-analysis.9
Clearly, DSA is an invasive procedure requiring an arterial
puncture. The non-invasive nature of CE-MRA renders it more
attractive to patients and clinicians alike. This must be balanced
against the potential for ill-judgedmanagement strategies based on
erroneous imaging. Acquisition artefact in CE-MRA may lead to
misguided attempts at percutaneous revascularisation or a decision
to proceed with unnecessary open revascularisation when there
was an endovascular option. Diabetic patients are generally regar-
ded as a high-risk group during vascular interventions and it is
essential that their risk be minimised. Thus, avoidance of futile
procedures and accurate determination of the optimal revascular-
isation options are essential.
6. Conclusion
At present, due to a lack of data, MRA cannot be recommended as
the ﬁrst-line diagnostic imaging modality of choice for infrage-
nicular vessels in diabetics with PAD. DSA could be considered an
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clusions cannot be drawn. Further high quality studies are needed.
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